Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2023) 142 (8): 687–699.

https://doi.org/10.1182/blood.2022018818

Published: 2023

Includes: Supplemental data

Journal Articles

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Kristin L Koenig, Prachi Jain, Ying Huang, Kerry A. Rogers, Seema A. Bhat, Jennifer A. Woyach, Michael R. Grever, Uma Borate, Alice S. Mims, Daniel Jones, Cecelia Miller, James S. Blachly, Adam S Kittai

Blood (2022) 140 (Supplement 1): 4071–4073.

https://doi.org/10.1182/blood-2022-168274

Published: 2022

Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 4166–4168.

https://doi.org/10.1182/blood-2022-167314

Published: 2022

Journal Articles

BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer A. Woyach, William G. Wierda, Catherine C. Coombs, Katharine L. Lewis, John G. Gribben, Maricer P. Escalon, Matteo Ceccarelli, Xiaoling Wu, Anthony R. Mato

Blood (2022) 140 (Supplement 1): 12427–12428.

https://doi.org/10.1182/blood-2022-157589

Published: 2022

Journal Articles

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle Brander, Michael Tees, Sameer A. Parikh, Tycel J. Phillips, Razi Ghori, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 7004–7006.

https://doi.org/10.1182/blood-2022-163596

Published: 2022

Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 497–498.

https://doi.org/10.1182/blood-2022-168345

Published: 2022

Journal Articles

Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 8746–8747.

https://doi.org/10.1182/blood-2022-169949

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 9368–9372.

https://doi.org/10.1182/blood-2022-159425

Published: 2022

Journal Articles

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2022) 140 (Supplement 1): 9865–9867.

https://doi.org/10.1182/blood-2022-159542

Published: 2022

Journal Articles

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Jyotsana Singh, Daisy Diaz Rohena, Chaomei Liu, Bailey Slawin, Janani Ravikrishnan, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 9857–9858.

https://doi.org/10.1182/blood-2022-168391

Published: 2022

Journal Articles

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Claire Hinterschied, Fiona Brown, Janani Ravikrishnan, JoBeth Helmig-Mason, Kaylee R. Harrison, Aneeq Yasin, Shelby Sloan, Mackenzie Long, Neha Bhagwat, Kris Vaddi, Peggy Scherle, Jennifer A. Woyach, Selina Chen-Kiang, Olivier Elemento, Jihye Paik, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 3118–3119.

https://doi.org/10.1182/blood-2022-167712

Published: 2022

Journal Articles

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Matthew S. Davids, Jeff P. Sharman, Toby A. Eyre, Jennifer A. Woyach, Paulo Andre P. de Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd

Blood (2022) 140 (Supplement 1): 4173–4175.

https://doi.org/10.1182/blood-2022-157018

Published: 2022

Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 7050–7052.

https://doi.org/10.1182/blood-2022-157060

Published: 2022

Journal Articles

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

James S. Blachly, Deborah M. Stephens, J Christine Ye, Nicole Lamanna, Nitin Jain, Michael Niesman, Kai Zhang, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 2324–2325.

https://doi.org/10.1182/blood-2022-171203

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 2316–2320.

https://doi.org/10.1182/blood-2022-159497

Published: 2022

Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller

Blood (2022) 140 (Supplement 1): 7016–7017.

https://doi.org/10.1182/blood-2022-163753

Published: 2022

Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 4127–4132.

https://doi.org/10.1182/blood-2022-159035

Published: 2022

Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd

Blood (2022) 140 (Supplement 1): 9873–9875.

https://doi.org/10.1182/blood-2022-162394

Published: 2022

Journal Articles

uMRD: “the” endpoint or “an” endpoint for CLL?

Adam S. Kittai, Jennifer A. Woyach

Blood (2022) 140 (8): 797–798.

https://doi.org/10.1182/blood.2022016927

Published: 2022

Journal Articles

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

Gage S. Black, Xiaomeng Huang, Yi Qiao, Szabolcs Tarapcsak, Kerry A. Rogers, Shrilekha Misra, John C. Byrd, Gabor T. Marth, Deborah M. Stephens, Jennifer A. Woyach

Blood (2022) 140 (4): 401–405.

https://doi.org/10.1182/blood.2021015132

Published: 2022

Includes: Supplemental data

NARROW

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

uMRD: “the” endpoint or “an” endpoint for CLL?

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only